Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $370.17 and traded as low as $315.00. Genmab A/S shares last traded at $324.07, with a volume of 821 shares traded.
Genmab A/S Stock Down 0.5 %
The firm’s 50 day simple moving average is $329.62 and its 200-day simple moving average is $369.51.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its earnings results on Tuesday, November 7th. The company reported $4.72 earnings per share (EPS) for the quarter. Genmab A/S had a net margin of 25.54% and a return on equity of 15.03%. The firm had revenue of $692.80 million for the quarter.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Five stocks we like better than Genmab A/S
- Options Trading – Understanding Strike Price
- 3 large caps with red hot RSIs with upside
- Insider Trading – What You Need to Know
- Johnson Controls International: Nothing but upside for investors
- Investing in Blue-Chip Stocks
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.